Varenicline: quantifying the risk

CMAJ. 2011 Sep 6;183(12):1405; author reply 1405, 1407. doi: 10.1503/cmaj.111-2071.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Benzazepines / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Humans
  • Nicotinic Agonists / adverse effects*
  • Quinoxalines / adverse effects*
  • Varenicline

Substances

  • Benzazepines
  • Nicotinic Agonists
  • Quinoxalines
  • Varenicline